Leaders in the Study of Allosteric Modulation to Discuss Latest Research at Allosteric and Orthosteric Modulato...( Arrowhead&rs...),Health

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Minneapolis, Minnesota (PRWEB) November 4, 2009 -- Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress, scheduled to take place in Philadelphia, PA on January 25 and January 26, 2010, will highlight key developments in the field of allosteric and orthosteric modulator drug discovery and clinical development.

Our speakers will discuss key developments in the field, including the challenges facing researchers, the opportunities for pharma and recent successes in the field.

Allosteric modulators are on the cutting edge of small molecule drug discovery, and therefore, are generating a great deal of excitement among researchers. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Since orthosteric modulators need to compete with natural ligands, they require higher doses, raising safety issues. Allosteric modulators do not compete and may therefore be effective at lower, safer doses.

Arrowhead’s 2010 Allosteric and Orthosteric Modulator Congress will highlight many key developments in the field. Conference attendees will come away with a better understanding of the following topics:

- Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders
- Dualsteric GPCR testing
- Allosteric modulation of GPCRs and transporters for the treatment of depression
- Structure-function approaches to understanding allosteric modulation of GPCRs
- Allosteric modulation of purine receptors
- Discovery of small molecule GPCR modulators
- Muscarinic receptors/GPC
'/>"/>